Gilead Sciences (NASDAQ:GILD) perks up 6% premarket on light volume on the heels of reports that its experimental antiviral remdesivir has helped critically ill COVID-19 patients recover.
14 Americans with an average age of 75 who
contracted SARS-CoV-2 infection on the Diamond Princess cruise ship were
treated with the drug at hospitals in Japan.
After two weeks, all survived and more than half
recovered. Five Americans remain critically ill. A total of 17 patients
received daily intravenous treatment for 10 days.
The ship was placed under two-week quarantine on
February 5 after docking in Yokohama. More than 700 passengers and crew
tested positive. Eight died.
Remdesivir (GS-5734), a nucleotide prodrug that
blocks a key enzyme needed for viral replication, is also being
developed for Ebola virus infection.
https://seekingalpha.com/news/3551485-gilead-up-6-premarket-on-encouraging-action-of-remdesivir-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.